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Colorectal Cancer Screening
(Continued from page 1)
cancers, when they are curable. “If we
can find it early, we can cure it,” said
Stanley Hamilton, M.D., a professor and
head of M. D. Anderson’s Division of
Pathology and Laboratory Medicine.
The biology of colorectal cancer
makes it particularly amenable to
screening: colorectal cancers are
associated with a low probability of
metastasis in early-stage disease, and a
variety of effective screening tools can
be employed to detect polyps and earlystage cancer. “It is therefore frustrating
to see patients present with metastatic
colorectal cancer who have never been
screened,” Dr. Hamilton said.
The screening tools of today
Current recommendations call
for colorectal cancer screening in the
general population after age 50 using
flexible sigmoidoscopy and a fecal
occult blood test (FOBT), doublecontrast barium enema, or colonoscopy.
Medically, all of these tools are very
effective, but they are not ideal, and
compliance is difficult to achieve.
Colonoscopy has some advantages
over other methods because it provides
direct visualization of the entire colon,
along with the opportunity to sample
or remove significant lesions. However,
colonoscopy is more expensive and more
invasive than many other screening
methods, and it carries a higher risk of
complications. Moreover, it is not covered
by many health insurance plans as a
primary screening device. “So, should
we be doing it? Yes,” said Dr. Hamilton,
“because this is one of the cancers where
screening will make a difference in the
number of deaths today.”
But the fact is that most people are not
eager to undergo any of the colorectal
cancer screening procedures currently
available. Therefore, in addition to efforts
to encourage screening by raising awareness of its benefits, research is under way
to find screening tools that will be better
accepted and more readily used.
A better FOBT
FOBT is the least invasive of
the screening methods, but it must
be used in combination with other
screening tests. A new type of FOBT—
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an immunochemical method—employs
antibodies to detect hemoglobin in stool
and has significant advantages over the
traditional guaiac-based method. One
advantage is that it does not react with
ingested food, vitamins, or drugs to cause
false-positive test results. Another is that
the specimen is collected from the surface
of the stool with a brush and transferred
to a card, a much easier collection method
than that required for guaiac-based
testing. Data from trials in large screening
populations are not yet available, but
based on the known enhanced sensitivity
and specificity and other advantages of
this method, the “American Cancer
Society Guidelines for the Early Detection
of Cancer, 2004” now recommends its
use over guaiac-based testing.
New visualization tools
Two new visualization techniques
have attracted the attention of the public
and the medical community, but neither
is ready for use as a large-scale screening
test. Computed tomographic (CT)
colonography, popularly known as
“virtual colonoscopy,” is an imaging
procedure in which a series of helical CT
scans of the patient’s colon are rendered
by computer into slices that can be
visualized as still, rotatable images or
serially combined to provide a threedimensional tour of the colon. So far, this
technique has been evaluated only in
small trials, mostly conducted in diagnostic (rather than screening) settings in
higher-risk patients. The results of those
studies indicate that CT colonography is
comparable to conventional colonoscopy
for the detection of neoplasms and polyps
larger than 10 mm but may be less
effective at detecting smaller polyps.
Although CT colonography may
eventually become an important
and widely used screening tool, a few
obstacles must be overcome first. The
amount of irradiation required for CT
colonography is a concern, and the
technique requires bowel preparation
and insufflation (the two factors that
account for most of the objections to
colonoscopy) but does not allow for
removal of polyps during the procedure,
as does colonoscopy. In addition, CT
colonography requires a radiologist

experienced with the technique (and the
learning curve is somewhat high), and no
standards exist for performing or interpreting the scans. CT colonography is
performed at M. D. Anderson as part of
research studies, but according to Dr.
Levin, it is not ready to be used as
standard care. “It is not specific enough
in differentiating between significant and
nonsignificant lesions inside and outside
of the colon and therefore may prompt
additional, unnecessary testing,” he said.
“Nevertheless, the technique is evolving
rapidly and may become much easier
to perform and thus more acceptable
to the public.”
Capsule video endoscopy—the
“camera-in-a-capsule” technique—has
also attracted a good deal of attention.
When swallowed, the capsule provides
approximately eight hours of videography
of the digestive tract. To date, the battery
life of the device is one of its limiting
factors: it usually runs out before the
capsule reaches the lower intestinal tract.
Nevertheless, it has been shown to be
safe and effective in animal and clinical
studies. The wider lumen of the colon
poses additional challenges in visualization, so major refinements in equipment
and technique will be needed before
capsule video endoscopy can be considered for the screening or diagnosis of
colorectal cancer.
Genetic and proteomic
tumor markers
In the near future, testing stool for
tumor DNA may prove more effective
than testing for occult blood. Tumors
bleed intermittently, but they shed
DNA constantly, so markers would be
present in any stool sample. Researchers
are still determining the best set of
markers to include in a test to screen
the general population. For more than
a decade, Dr. Levin has been collaborating with scientists at The Johns Hopkins
University to develop a method for
molecular testing.
Yet another area of promise and
intense research is serum proteomics—
the study of protein patterns circulating
in the blood. Such patterns can have a
high predictive value, and researchers
are working to identify these patterns
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The University of Texas
M. D. Anderson Cancer Center
President

John Mendelsohn, M.D.

Anderson Network volunteer

ExecuUve Vice President
and Chief Academic Officer

I was diagnosed with
adenocarcinoma of the
duodenum in the summer
of 1999 and underwent
a Whipple procedure at
M. D. Anderson Cancer
Center. As I was recover
ing from my surgery, a
volunteer entered my room and asked if I
was feeling up to a conversation. I quickly
said no, and she told me that she was a
20-year breast cancer survivor and could
certainly understand where I was at that
moment, and then she left. Even in my
drugged state, her words "20-year survivor"
played over and over in my mind as a
delightful vision. To this day, I do not
know who she was, but she made a huge
impact on me.

Vice President for Academic Affairs

"Those who bring sunshine to the
lives of others cannot keep it from
themselves."
- Sir James Barrie
Today, I am a four-year survivor and a
volunteer at M. D. Anderson. Where else
in this world could I make faces light up by
simply walking into a room and saying, "I
was in one of these beds four years ago"?
The most frequent response I get is, "You
look good!" These patients are receiving the
same inspiration that I did four years ago
from that unnamed volunteer and from the
Anderson Network volunteers who coached
me through my experience by phone and
in person.
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M argaret L l<rlpkc, Ph.D.

In a world in which many of us feel that
we can be easily replaced in our day jobs, this
position of survivor/volunteer is one that I am
uniquely qualified to fill. When people ask me
why I volunteer, I am likely to tell them that
I am "turning lemons into lemonade." I am
hoping to make a difference as so many have
done for me these past few years. As an added
benefit, I also am reminded weekly of how
blessed I am to continue to experience a full
and healthy life.

"We make a living by what we get,
but we make a /ife by what we give. "
- Winston Churchill
I have been delighted by the profession
alism of the Anderson Volunteer Services
organization: they are dedicated to making
sure that every patient has the experience
of being in a caring place each and every
day and night. The doctors and nurses at
M. D. Anderson also volunteer their care
and concern every day. There was my
surgeon, who returned my call to his pager
while taking his daughters to a record store
on a Saturday; my radiation oncology nurse,
who offered me her home phone number
to call if I needed her after hours (and
I really did); and many others who took
just a moment to give a smile or an under
standing response to a question. They all
made a big difference during this ordeal
of mine.
My efforts as a volunteer are dedicated
to all of you who have made such a differ
ence in my life!

Stephen P. Tom850Vlc, PhD.

Director, Department of
Sclentlftc Publications

Walter J. Pagel

Managing Editor
Dawn Chalairc
Contributing Editors

David Galloway

Surmi Hose:nann
BcthNotron

Production Editor
Katie Prout Matias
Design

The Very Idea�

Photography

Jim Lemoine

Editorial Board

Rena Sellin, M.D., Ch,:,ir
James Arens, M.D.
Therese Bevers, M.D.
Thomas D. Brown, M.D.
Thomas Buth, M.D.
David Callender, M.D.
Ka Wah Chan, M.D.
Charles Conrad, M.D.
Joseph Corriere, M.D.
Steven Curley, M.D.
Eduardo Diaz, Jr., M.D.
Larry Drive� M.D.
Car:nellca &calante, M.D.
Luis Fayad, M.D.
Mtchacl Fisch, M.D.
Frank Fossclla, M.D.
Lewis Foxhal� M.D.
Robert G age� M.D.
Sergio Gira It, M.D.
Chui S. Ha, M.D.
Beverly Handy, M.D.
Marryn Howgill
Charles Koller, M.D.
Jeffrey Lee, M.D.
Charles Lcvcnb.ck, M.D.
Paul Mansfield, M.D.
Moshe Mao� M.D.
Shrcvaskumar Patel, MD.
Geof'frcy Robb, M.D.
Kenneth Rolston, MD.
Erle Stro:n, M.D.
Joseph Swafford, MD.
Christopher Wood, M.D.
Alan Yasko, M.D.
P11Mshed bJ the Department ofScientific Ptd>Nrorions-234,
The Unh,rsiey of Texas M. D. Anderson Cancer Center,
1515 Holrombe B01dei,,,-d, H01u.,n, Texas 77030,
713-792-3305.
Madepos,ilkin pardry agif,from the/ate Mrs. Harry
C. W,ess. Notprintedaes,aree,pense.

©2004 The Uru«rsiey o{Texas M. D. Anderson Cancer Center Printed on recycled paper

@

